311 related articles for article (PubMed ID: 16430195)
1. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.
Barroso L; Treanor J; Gubareva L; Hayden FG
Antivir Ther; 2005; 10(8):901-10. PubMed ID: 16430195
[TBL] [Abstract][Full Text] [Related]
2. Intravenous peramivir for treatment of influenza in hospitalized patients.
Ison MG; Fraiz J; Heller B; Jauregui L; Mills G; O'Riordan W; O'Neil B; Playford EG; Rolf JD; Sada-Diaz E; Elder J; Collis P; Hernandez JE; Sheridan WP
Antivir Ther; 2014; 19(4):349-61. PubMed ID: 23985625
[TBL] [Abstract][Full Text] [Related]
3. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.
Hayden FG; Treanor JJ; Fritz RS; Lobo M; Betts RF; Miller M; Kinnersley N; Mills RG; Ward P; Straus SE
JAMA; 1999 Oct; 282(13):1240-6. PubMed ID: 10517426
[TBL] [Abstract][Full Text] [Related]
4. Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza.
Mancuso CE; Gabay MP; Steinke LM; Vanosdol SJ
Ann Pharmacother; 2010; 44(7-8):1240-9. PubMed ID: 20516360
[TBL] [Abstract][Full Text] [Related]
5. Peramivir for the treatment of influenza.
Shetty AK; Peek LA
Expert Rev Anti Infect Ther; 2012 Feb; 10(2):123-43. PubMed ID: 22339187
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
[TBL] [Abstract][Full Text] [Related]
7. Post-marketing safety evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir: A drug-use investigation in patients with high risk factors.
Komeda T; Ishii S; Itoh Y; Sanekata M; Yoshikawa T; Shimada J
J Infect Chemother; 2016 Oct; 22(10):677-84. PubMed ID: 27497712
[TBL] [Abstract][Full Text] [Related]
8. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults.
Ison MG; Hui DS; Clezy K; O'Neil BJ; Flynt A; Collis PJ; Simon TJ; Alexander WJ
Antivir Ther; 2013; 18(5):651-61. PubMed ID: 23111657
[TBL] [Abstract][Full Text] [Related]
9. Oral oseltamivir in human experimental influenza B infection.
Hayden FG; Jennings L; Robson R; Schiff G; Jackson H; Rana B; McClelland G; Ipe D; Roberts N; Ward P
Antivir Ther; 2000 Sep; 5(3):205-13. PubMed ID: 11075941
[TBL] [Abstract][Full Text] [Related]
10. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza.
Sidwell RW; Smee DF
Expert Opin Investig Drugs; 2002 Jun; 11(6):859-69. PubMed ID: 12036429
[TBL] [Abstract][Full Text] [Related]
11. Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials.
Whitley R; Laughlin A; Carson S; Mitha E; Tellier G; Stich M; Elder J; Alexander WJ; Dobo S; Collis P; Sheridan WP
Antivir Ther; 2015; 20(7):709-19. PubMed ID: 25318121
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza.
Hayden FG; Treanor JJ; Betts RF; Lobo M; Esinhart JD; Hussey EK
JAMA; 1996 Jan 24-31; 275(4):295-9. PubMed ID: 8544269
[TBL] [Abstract][Full Text] [Related]
13. Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants.
Sato M; Ito M; Suzuki S; Sakuma H; Takeyama A; Oda S; Watanabe M; Hashimoto K; Miyazaki K; Kawasaki Y; Hosoya M
Antimicrob Agents Chemother; 2015 Mar; 59(3):1643-9. PubMed ID: 25547357
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis.
Lee J; Park JH; Jwa H; Kim YH
Yonsei Med J; 2017 Jul; 58(4):778-785. PubMed ID: 28540991
[TBL] [Abstract][Full Text] [Related]
15. Peramivir: A Review in Uncomplicated Influenza.
Scott LJ
Drugs; 2018 Sep; 78(13):1363-1370. PubMed ID: 30196350
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report.
Harada N; Shibata W; Koh H; Takashita E; Fujisaki S; Okamura H; Nanno S; Yamada K; Nakamae H; Hino M; Kakeya H
BMC Infect Dis; 2020 Jul; 20(1):478. PubMed ID: 32631240
[TBL] [Abstract][Full Text] [Related]
17. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients.
Kohno S; Kida H; Mizuguchi M; Hirotsu N; Ishida T; Kadota J; Shimada J;
Antimicrob Agents Chemother; 2011 Jun; 55(6):2803-12. PubMed ID: 21464252
[TBL] [Abstract][Full Text] [Related]
18. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (I): a drug use investigation.
Komeda T; Ishii S; Itoh Y; Ariyasu Y; Sanekata M; Yoshikawa T; Shimada J
J Infect Chemother; 2014 Nov; 20(11):689-95. PubMed ID: 25131292
[TBL] [Abstract][Full Text] [Related]
19. Peramivir: an intravenous neuraminidase inhibitor.
McLaughlin MM; Skoglund EW; Ison MG
Expert Opin Pharmacother; 2015; 16(12):1889-900. PubMed ID: 26153242
[TBL] [Abstract][Full Text] [Related]
20. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.
Hayden FG; Atmar RL; Schilling M; Johnson C; Poretz D; Paar D; Huson L; Ward P; Mills RG
N Engl J Med; 1999 Oct; 341(18):1336-43. PubMed ID: 10536125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
